Welcome to our dedicated page for Edap Tms SEC filings (Ticker: EDAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EDAP TMS SA filings document a France-based medical-device issuer with Nasdaq-listed American depositary shares, each representing one ordinary share. Its current reports cover operating results for the HIFU business, Focal One robotic HIFU system sales and procedure trends, ESWL and Distribution revenue, investor presentation materials, and product regulatory updates such as FDA 510(k) clearances for Focal One enhancements.
The company’s SEC disclosures also record capital-structure and financing matters, including a European Investment Bank credit facility and related warrants to purchase ordinary shares. Governance filings address board composition, committee assignments, and shareholder-vote matters, while foreign-issuer reports provide formal disclosure around EDAP’s therapeutic ultrasound strategy, risk statements, and public-company reporting obligations.
EDAP TMS entered into a letter of intent for a EUR 36 million credit facility with the European Investment Bank to support its robotic energy-based therapy business. The funding is intended to expand adoption of the Focal One® Robotic HIFU system in focal therapy for early-stage prostate cancer and to accelerate development of new clinical indications. Pending final legal documentation, the facility is expected to close no later than the end of calendar year 2025 and is described as low-interest funding that can be drawn in tranches as needed.